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Background: Pulmonary pleomorphic carcinoma (PPC) is a rare type of non-small-cell lung cancer that belongs to
the family of sarcomatoid carcinomas and is associated with poor prognosis. We investigated the expressions of
tumor-related genes in resected PPC specimens.
Methods: Specimens resected from patients with PPC from July 2006 through April 2012 were investigated. Tumor
segments were collected from the specimens by micro-dissection to extract mRNA, then RT-PCR was performed
according to Dannenberg’s tumor profile method for semi-quantitation of tumor-related gene mRNA. To compare
with other types of lung cancer, data from stage-matched adenocarcinoma (AC) and squamous cell carcinoma
(SCC) cases in our database were also examined.
Results: The gene expression levels of thymidylate synthase were significantly higher in PPC and SCC as compared
to the AC specimens (p < 0.001). The levels of dihydropyrimidine dehydrogenase and thymidine phosphorylase
mRNA in PPC showed a similar tendency to those in SCC, in contrast to AC. Furthermore, the expression level of
excision repair cross-complementation group 1 mRNA in PPC specimens was similar to that reported in NSCLC,
while the level of vascular endothelial growth factor (VEGF) expression was higher as compared to that reported for
colorectal cancer.
Conclusions: Although gene expression of tumor cannot be directly correlated to its sensitivity for anti-cancer
drugs, it is likely that PPC tumors are not sensitive to anti-metabolic drugs. Anti-VEGF therapy may be a candidate
for PPC, while cisplatin also remains a viable option.
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A pulmonary pleomorphic carcinoma (PPC) is a rare type
of non-small-cell lung cancer (NSCLC) that belongs to the
family of sarcomatoid carcinomas [1] and is associated
with poor prognosis [2–4]. Most affected patients experi-
ence recurrence and die during the first year after surgical
intervention [2]. In general, the chemo-sensitivity of PPC
is considered to be lower than that of other types of
NSCLC, though Kawano et al. conducted a histoculture
drug response assay and reported that some anticancer
drugs may be effective [3]. Recently, the expression of
various tumor-related genes have been reported to correl-
ate to chemo-sensitivity and prognosis in several types of
cancer [5–7]. However, few reports have been published* Correspondence: yuji-m@dokkyomed.ac.jp
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the present study, we investigated the expressions of
tumor-related genes in this rare tumor to establish an ap-
propriate treatment strategy.Methods
Resected specimens from patients with PPC who under-
went lung resection from July 2006 through April 2012 at
our institutions were investigated. Those from patients who
received preoperative induction therapy including chemo-
therapy or chemoradiotherapy were excluded. To compare
with other types of lung cancer, 40 stage-matched adeno-
carcinoma (AC) and 35 squamous cell carcinoma (SCC)
cases in our database [8] were also examined. Dokkyo
Medical University Hospital Ethics Committee approved
this retrospective study (#24035) and waived the need for
patient consent for analysis of the results.rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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Excised specimens were thinly sliced, then tumor segments
were collected by micro-dissection to extract mRNA. RT-
PCR was performed according to Danenberg’s tumor pro-
file (DTP) method [9] for semi-quantitation of mRNA of
tumor-related genes (Response Genetics Inc., New York,
USA), including thymidylate synthase (TS), dihydropyr-
imidine dehydrogenase (DPD), thymidine phosphoryl-
ase (TP), excision repair cross-complementation group
1 (ERCC1), vascular endothelial growth factor (VEGF),
and topoisomerase-1 (TOPO1). In brief, a laser cap-
tured micro-dissection technique was used on 10-μm
sections with a magnification of 100x to obtain only
cancer cells. Next, 1500–2000 round spots 80 μm in
diameter were dissected for each case, from which total
RNA was extracted. Real-time quantitative reverse
transcription-PCR assays were performed on those sam-
ples using an ABI 7700 and TaqMan Probes. The level
of ß-actin mRNA was used as a reference gene. Relative
gene expression values are expressed as a ratio of PCR
products of the gene of interest to that of the internal
reference gene ß-actin.Statistics
Values are shown as the mean ± SD. Analysis of variance
(ANOVA) was used for comparing among 3 groups, then
Tukey’s post-hoc test was used when significance was
found. Differences were considered significant at P < 0.05,
with borderline significance considered at P < 0.10.Table 1 Patient characteristics
Case Age/Sex Stage Chemotherapy
1 70/M T2bN1M0 (+)
AMR
2 75/M T2bN1M0 (−)
3 57/M T2aN0M0 (+)
AMR, CBDCA + P
4 77/M T2bN0M0 (−)
5 68/M T2aN0M0 (+)
DTX + TS1
6 80/M T3N0M0 (−)
7 54/M T3N0M0 (−)
8 47/M T2bN0M0 (+)
TS1, CDDP + VNR
9 48/F T2aN1M1 (+)
CBDCA + DTX
10 73/M T2bN0M0 (−)
Each stage is presented based on the 7th UICC TNM classification
mo months, AMR amrubicin, CBDCA carboplatin, PTX paclitaxel, TS1 tegafur gimerac
aincomplete resection
boperative death due to cerebral infarctionResults
Among 536 patients who underwent surgery for primary
lung cancer at our institution, 10 had PPC (1.9 %). They
consisted of 9 men and 1 woman, with a mean age of
64.9 years (range 47–80 years). Patient characteristics
are shown in Table 1.
Gene expression levels of the nucleotide-metabolism-
related enzymes TS, DPD, and TP in PPC were com-
pared to those in AC and SCC specimens. The relative
gene expression value of TS was 5.65 ± 3.46 in PPC,
1.59 ± 0.86 in AC, and 4.68 ± 3.71 in SCC (Fig. 1). That
value was significantly higher in PPC and SCC speci-
mens as compared to AC (p < 0.001). In contrast, the
relative gene expression value for DPD was 2.49 ± 1.70,
2.20 ± 1.18, and 1.59 ± 1.34, respectively (Fig. 2), which
was greater in PPC and AC than in SCC, with borderline
significance (p = 0.0649). That of TP in the specimens
was 14.81 ± 14.99, 9.17 ± 6.51, and 14.61 ± 11.06, respect-
ively (Fig. 3), with no significant difference between AC
and SCC, while that of AC was significantly lower as
compared to SCC (p < 0.05).
Other tumor-related gene expression levels are shown
in Table 2. The relative gene expression values of
ERCC1, VEGF, and TOPO1 in the PPC specimens were
1.68 ± 0.66, 8.53 ± 6.44, and 2.55 ± 0.73, respectively.
Discussion
PPC is a rare type of tumor and accounted for only
1.9 % of resected lung cancer cases examined in the
present study. Although affected patients are known toRelapse Status
Distant 16 mo Dead
(−) 39 mo Alive
Distant 42 mo Alive
TX
Distant 9 mo Dead
(−) 57 mo Alive
Distant 57 mo Alive
Locala 2 mo Dead
Distant 12 mo Dead
, CBDCA + PTX
Distant 14 mo Dead
(−)b 2 mo Dead
il oteracil, DTX docetaxel, VNR vinorelbine
Fig. 1 Comparison of relative gene expression of thymidylate synthase in cancer specimens. PPC, pulmonary pleomorphic carcinoma; AC,
adenocarcinoma; SCC, squamous cell carcinoma
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on this tumor. This is the first known investigation of
tumor-related gene expression in resected PPC speci-
mens. Our results showed a significant increase in the
level of TS mRNA in PPC compared to AC specimens.
The gene expression levels of the nucleotide-
metabolism-related enzymes TS, DPD, and TP in PPC
were compared to those in stage-matched NSCLC cases
listed in our database. Anti-metabolic drugs, such as
pemetrexed, gemcitabine, and 5-fluorouracil and its de-
rivatives, are widely used as cancer chemotherapy
agents, and their effects include inhibition of TS, as
well as incorporation of its metabolites into RNA and
DNA. Lower TS activity is thought to be correlated
with greater sensitivity to anti-metabolic drugs [8, 9].
The present findings showed that gene expression
levels of TS mRNA in PPC were significantly higher
than in AC, whereas those of DPD and TP mRNA in
PPC were similar to those in SCC, in contrast to AC.Fig. 2 Comparison of relative gene expression of dihydropyrimidine dehyd
carcinoma; AC, adenocarcinoma; SCC, squamous cell carcinomaGenerally, AC is thought to be more sensitive to anti-
metabolic drugs as compared to SCC. Our results indicate
that it is unlikely that PPC is sensitive to anti-metabolic
drugs, which agrees with clinical experience.
The expression levels of other tumor-related genes
were also examined. Unfortunately, we were not able to
examine stage-matched AC and SCC specimens, thus
used previously reported data (Table 2).
ERCC1 protein is involved in nucleotide excision re-
pair of damaged DNA and determination of ERCC1
mRNA expression may have be clinically useful for can-
cer treatment, because one of the mechanisms of resist-
ance to platinum chemotherapy drugs is correlated
with high ERCC1 activity [10, 11]. We found that the
gene expression level of ERCC1 mRNA in PPC speci-
mens was similar to that reported in NSCLC. However,
findings are limited and do not fully reveal the efficacy
of platinum-based chemotherapy, of which cisplatin is
a likely candidate for PPC treatment.rogenase in cancer specimens. PPC, pulmonary pleomorphic
Fig. 3 Comparison of relative gene expression of thymidine phosphorylase in cancer specimens. PPC, pulmonary pleomorphic carcinoma; AC,
adenocarcinoma; SCC, squamous cell carcinoma
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and anti-VEGF therapies are important for treatment of
certain cancers, because solid tumors do not grow be-
yond a limited size without an adequate blood supply
provide by angiogenesis using VEGF signals. VEGF gene
expression has been shown to be higher than that of
colorectal cancer, thus anti-VEGF therapy may useful for
PPC patients. Furthermore, TOPO-1, involved in cell
division, is a target of some anti-cancer drugs, such as
irinotecan, topotecan, and camptothecin. Nevertheless,
there are few reports of a correlation between clinical
outcome and TOPO-1 mRNA level determined by the
DTP method, though TOPO-1 gene expression was
found to be lower than that of thymic cancer.
The present study is limited by its design as an institu-
tional report of a small population, due to the rarity of
the disease. Additional studies and case accumulation
are necessary.
Conclusion
Gene expression levels of nucleotide-metabolism-related
enzymes in PPC showed a pattern similar to those in
SCC, while they were different as compared to AC speci-
mens. Although gene expression of tumor cannot beTable 2 Mean gene expression values of ERCC1, VEGF, and
TOPO1 in PPC and other organ carcinoma specimens by DTP
method
ERCC1 VEGF TOPO1
NSCLC [6] n = 283 1.65 - -
Colorectal cancer [7] n = 31 - 3.79 -
Thymic cancer [12] n = 14 3.62 10.06 4.02
PPC (present study) n = 10 1.68 8.53 2.55
ERCC1 excision repair cross-complementation group 1, VEGF vascular endothelial
growth factor, TOPO1 topoisomerase-1, PPC pulmonary pleomorphic carcinoma,
DTP Danenberg’s tumor profiledirectly correlated to its sensitivity for anti-cancer drugs,
it is unlikely that PPC is sensitive to anti-metabolic
drugs. On the other hand, anti-VEGF therapy may be ef-
fective for PPC, while cisplatin also remains a viable
candidate.
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